[CAS NO. 5355-16-8] Diaveridine
PRODUCTS SPECIFICATIONS [5355-16-8]
DESCRIPTION [5355-16-8]
Overview
| MDL | MFCD00057349 |
|---|---|
| Molecular Weight | 260.29 |
| Molecular Formula | C13H16N4O2 |
| SMILES | NC1=NC=C(CC2=CC=C(OC)C(OC)=C2)C(N)=N1 |
Summary
Diaveridine (EGIS-5645) is a dihydrofolate reductase ( DHFR ) inhibitor with a K i of 11.5 nM for the wild type DHFR and also an antibacterial agent.
In Vitro
Diaveridine is a dihydrofolate reductase (DHFR) inhibitor with a K i of 11.5 nM for the wild type DHFR and also an antibacterial agent [1] . Treatments with Diaveridine for 90 min have a strong bactericidal effect on S. typhimurium TA1535, and no bacterial growth is observed at 10μg/mL or more. Without metabolic activation, treatment with Diaveridine for 48 h, but not 24 h, causes a dose-dependent, significant increase in the frequency of aberrant metaphases. At 100 μg/mL, 60% of the metaphases contain chromosome aberrations [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
The sperm abnormality of the Diaveridine (DVD) treatment groups at all dose levels (Diaveridine, 128 to 512 mg/kg) shows no significant differences compare with the negative control group. There are no significant differences of micronucleus between the negative control group and the Diaveridine treatment groups (Diaveridine, 128 to 512 mg/kg). The chromosome aberration of the Diaveridine treatment groups at all dose levels and the negative control group are significantly lower than those in the positive control group treated with cyclophosphamide (P<0.05), indicating that Diaveridine at the doses studied does not cause abnormal chromosome aberration. The results demonstrate that the Diaveridine administration does not produce significant changes in the ratio of organ-to-body weight, compare with the negative control group in the end period of the study [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 33.33 mg/mL ( 128.05 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.8419 mL | 19.2093 mL | 38.4187 mL |
| 5 mM | 0.7684 mL | 3.8419 mL | 7.6837 mL |
| 10 mM | 0.3842 mL | 1.9209 mL | 3.8419 mL |
References
- [1] Sirichaiwat C et al. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. J Med Chem 47:345-54 (2004).
- [2] Ono T, et al. The genotoxicity of diaveridine and trimethoprim. Environ Toxicol Pharmacol. 1997 Sep;3(4):297-306.
- [3] Wang J, et al. Acute, mutagenicity, teratogenicity and subchronic oral toxicity studies of diaveridine in rodents. Environ Toxicol Pharmacol. 2015 Sep;40(2):660-70.
Synonyms